Publicacions
-
Vicente-Garces C, Esperanza-Cebollada E, Montesdeoca S, Torrebadell-Burriel M, Rives-Solà S, Dapena JL, Català-Temprano A, Conde N, Camós-Guijosa M and Vega-García N.
Technical Validation and Clinical Utility of an NGS Targeted Panel to Improve Molecular Characterization of Pediatric Acute Leukemia
Frontiers in Molecular Biosciences . 9: 854098-854098. Nº de cites: 4
-
Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz MJ, Campbell M, Cario G, Cazzaniga G, Escherich G, Harrison CJ, Heyman M, Hunger SP, Kiss C, Liu HC, Locatelli F, Loh ML, Manabe A, Mann G, Pieters R, Pui CH, Rives-Solà S, Schmiegelow K, Silverman LB, Stary J, Vora A and Brown PA.
Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium.
Blood . 139(12): 1785-1793. Nº de cites: 30
-
Marina Caballero Bellón, Faura A, Margarit A, Bobillo-Perez S, Català-Temprano A, Alonso-Saladrigues A, Conde N, Balaguer-Gargallo M, Rives-Solà S and Jordán-García I.
Outcomes for paediatric acute leukaemia patients admitted to the paediatric intensive care unit
EUROPEAN JOURNAL OF PEDIATRICS . 181(3): 1037-1045. Nº de cites: 6
-
Buechner J, Caruana I, Künkele A, Rives-Solà S, Vettenranta K, Bader P, Peters C, Baruchel A and Calkoen FG.
Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?
Frontiers in pediatrics . 9: 784024-784024. Nº de cites: 15
-
Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives-Solà S, Boyer MW, Hiramatsu H, Yanik GA, Driscoll T, Myers GD, Bader P, Baruchel A, Buechner J, Stefanski HE, Kalfoglou C, Nguyen K, Waldron ER, Thudium Mueller K, Maier HJ, Kari G and Grupp SA.
Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia
blood cancer discovery . 3(1): 66-81. Nº de cites: 88
-
Ortiz-Maldonado V, Rives-Solà S, Español-Rego M, Alonso-Saladrigues A, Montoro M, Magnano L, Giné E, Pascal M, Díaz-Beyá M, Castella M, Català-Temprano A, Faura A, Rodríguez-Lobato LG, Oliver-Caldes A, Martínez-Roca A, Rovira M, González-Navarro EA, Ortega JR, Cid J, Lozano M, Garcia-Rey E, Fernández S, Castro P, Jordán-García I, Villamor N, Aymerich M, Torrebadell-Burriel M, Deyà-Martinez A, Fernández de Larrea C, Benitez-Ribas D, Trias E, Varea S, Calvo G, Esteve J, Urbano-Ispizua A, Juan-Otero M and Delgado J.
Factors associated with the clinical outcome of patients with relapsed/refractory CD19 + acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy
Journal for ImmunoTherapy of Cancer . 9(12): 3644. Nº de cites: 15
-
Mesegue-Meda M, Alonso-Saladrigues A, Pérez-Jaume S, Comes-Escoda A, Dapena JL, Faura A, Conde N, Català-Temprano A, Ruiz-Llobet A, Zapico-Muñiz E, Camós-Guijosa M and Rives-Solà S.
Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia
HEMATOLOGICAL ONCOLOGY . 39(5): 687-696. Nº de cites: 7
-
Rubio-San-Simón A, Hladun Alvaro R, Juan Ribelles A, Castañeda-Heredia A, Guerra-García P, Verdú-Amorós J, Andrés M, Cañete A, Rives-Solà S, Pérez-Martínez A, Mora J, Patiño-García A, Lassaleta A, Llort A, Ramírez M, Mata C, Gallego S, Martín-Broto J, Cruz-Martínez O, Morales-La Madrid A, Solano P, Martínez Romera I, Fernández-Teijeiro A, Bautista F and Moreno L.
The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)
CLINICAL & TRANSLATIONAL ONCOLOGY . 23(12): 2489-2496. Nº de cites: 4
-
Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives-Solà S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM and Locatelli F.
Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial
blood advances . 5(14): 2901-2908. Nº de cites: 30
-
Vega-García N, Pérez-Jaume S, Esperanza-Cebollada E, Vicente-Garces C, Torrebadell-Burriel M, Jiménez-Velasco A, Ortega M, Llop M, Abad L, Vagace JM, Minguela A, Pratcorona M, Sánchez-Garcia J, García-Calderon CB, Gómez-Casares MT, Martín-Clavero E, Escudero A, Riñón M, Muñoz L, Velasco MR, García-Morín M, Català-Temprano A, Pascual A, Velasco P, Fernandez JM, Lassaletta A, Fuster JL, Badell I, Molinos-Quintana A, Molinés A, Guerra-Garcia P, Pérez-Martínez A, García-Abós M, Robles R, Pisa S, Adán R, Díaz de Heredia C, Dapena JL, Rives-Solà S, Ramirez M and Camós-Guijosa M.
Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment.
Frontiers in pediatrics . 8: 614521-614521. Nº de cites: 5